How to Switch from Saxenda to Foundayo (Orforglipron)

Saxenda (liraglutide 3.0mg) was FDA-approved for weight management in 2014 — making it one of the oldest GLP-1 weight loss medications. While it was groundbreaking at launch, next-generation options like Foundayo surpass it in every measurable way. For a full comparison of modern alternatives, see our best oral GLP-1 guide:

Factor	Saxenda	Foundayo
Weight loss	5-8% (SCALE trials)	12.4% (ATTAIN-1)
Dosing	Daily injection	Daily pill
Monthly cost	$1,349/mo	$149-349/mo
Injection	Yes (daily subcutaneous)	No (oral tablet)
Cold storage	Before first use	None needed
FDA approval	2014	April 2026
Molecule	Liraglutide (peptide)	Orforglipron (non-peptide)
Half-life	13 hours	~29-49 hours

This is the easiest upgrade in GLP-1 medicine: More weight loss, lower cost, no injections, no needles, no cold storage. If you're still on Saxenda in 2026, it's time to switch. Learn how to get Foundayo prescribed today.

While both are GLP-1 receptor agonists, the pharmacology differs significantly. For a broader comparison, see Foundayo vs Ozempic and Foundayo vs Wegovy:

• Saxenda (liraglutide): First-generation peptide GLP-1 analogue. 97% homology to human GLP-1. Short half-life (13 hours) requiring daily injection. Moderate receptor activation.
• Foundayo (orforglipron): Non-peptide small molecule GLP-1 receptor agonist. Completely different chemical structure. Longer half-life (~29-49 hours). Can be taken orally because it doesn't degrade in the stomach. Check drug interactions before starting.

Why Foundayo is more effective:

• Higher receptor occupancy at approved doses translates to greater appetite suppression
• Longer half-life provides more consistent GLP-1 receptor stimulation throughout the day
• Non-peptide structure allows higher effective doses via oral route

Think of it as upgrading from a flip phone to a smartphone — same basic function (GLP-1 activation), but everything else is better. If you eventually want even more weight loss, Foundayo can serve as a stepping stone to Zepbound (see Foundayo vs Zepbound).

Liraglutide and orforglipron are different molecules, so there's no direct conversion. For the complete titration plan, see our Foundayo dosing schedule guide. Start at Foundayo 0.8mg regardless of your Saxenda dose:

Saxenda Dose	Foundayo Start	Foundayo Target	Notes
0.6mg	0.8mg	2.5-5.5mg	Both starter doses
1.2mg	0.8mg	5.5-9mg	~8-12 weeks to target
1.8mg	0.8mg	9-14.5mg	~12-16 weeks
2.4mg	0.8mg	14.5-17.2mg	~16-20 weeks
3.0mg (max)	0.8mg	14.5-17.2mg	~16-20 weeks

Note on half-lives: Saxenda's liraglutide has a 13-hour half-life (vs Ozempic's 7-day half-life). This means liraglutide clears your system faster — within 2-3 days of stopping. The overlap with Foundayo's early doses provides sufficient coverage, but some patients notice a 1-2 day gap in appetite suppression during the transition. For other switch paths, see our injectable to oral GLP-1 guide.

Saxenda's side effect profile reflects its older, first-generation pharmacology. Foundayo's rates are higher but correspond to much greater efficacy. For a detailed timeline, see our week-by-week side effects guide:

• Nausea: Saxenda 39% → Foundayo 33.7% — improvement. See nausea management tips.
• Diarrhea: Saxenda 21% → Foundayo 23.1% — similar
• Constipation: Saxenda 19% → Foundayo 25.4% — higher on Foundayo. Try our constipation remedies.
• Vomiting: Saxenda 16% → Foundayo 24.0% — higher on Foundayo
• Injection site reactions: Saxenda 13.9% → Foundayo 0% — eliminated
• Headache: Saxenda 14% → Foundayo ~7% — improvement

Key advantage: Saxenda's daily injections cause injection site reactions in nearly 14% of patients — redness, itching, and bruising. Foundayo eliminates this entirely. Additionally, Saxenda's high nausea rate (39%) is actually worse than Foundayo's (33.7%), despite Saxenda's inferior weight loss results. Some patients also experience temporary hair changes or facial volume changes during rapid weight loss.

The cost savings from switching Saxenda to Foundayo are dramatic. See our full Foundayo pricing guide:

Saxenda: $1,349/month at list price. Novo Nordisk savings card may reduce this for insured patients.

Foundayo: $149-349/month (dose-dependent). Lilly savings card brings it to $25/month for commercially insured patients.

Annual savings at self-pay:

• Saxenda: $16,188/year
• Foundayo: $1,788-4,188/year
• You save: $12,000-14,400 per year

That's enough to fund a vacation, pay down debt, or invest in other health improvements — all while getting better weight loss results.

Hidden cost savings: No sharps containers, no cold storage needs, no injection supplies. Foundayo is just a pill in a bottle — no ancillary costs. Explore Amazon Pharmacy pricing and LillyDirect for the best deals.

Both Saxenda and Foundayo are FDA-approved for weight management, which simplifies the insurance picture compared to diabetes-to-weight-loss switches:

Coverage similarities:

• Both medications fall under obesity/weight management benefits — if your plan covers Saxenda, it likely covers Foundayo too
• Prior authorization requirements are often similar for both
• Step therapy: some plans may have already satisfied this requirement through your Saxenda use

Savings opportunities:

• Lilly's savings card: $25/month for commercially insured patients
• LillyDirect: streamlined ordering with integrated savings
• Amazon Pharmacy: competitive self-pay pricing
• Medicare: expanding coverage in 2026

The cost math: Even without any insurance or savings cards, switching from Saxenda ($1,349/mo) to Foundayo ($149-349/mo) saves you $1,000-1,200 per month. See our complete insurance coverage guide or explore the best GLP-1 options without insurance.